"Taari, Kimmo" - Selaus tekijän mukaan TUNICRIS-julkaisut
Viitteet 1-20 / 23
-
Allopurinol and prostate cancer survival in a Finnish population-based cohort
(21.03.2022)
article<p>BACKGROUND: Allopurinol is gout medication that inhibits uric acid formation. Its possible anti-carcinogenic properties have been under research in past years. Studies based on Taiwanese registries showed that ... -
Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
(2022)
article<p>Background: Drugs with histone deacetylase inhibitory (HDACi) properties have shown to decrease prostate cancer (PCa) cell growth in vitro. Methods: A cohort of 9261 PCa cases from the Finnish Randomized Study of ... -
Antidiabetic drugs and prostate cancer prognosis in a Finnish population-based cohort
(05 / 2021)
article<p>BACKGROUND: Hyperinsulemia and glycemic control may play a role as prostate cancer prognostic factors, while use of certain antidiabetic drugs, i.e metformin, could improve the prognosis. We examined the link ... -
Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia
(2022)
article<p>Background: Diabetes has been associated with an increased risk of benign prostatic hyperplasia (BPH). However, the role of antidiabetic drugs as a BPH risk factor is unclear. The objective of our study was to ... -
Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
(26.02.2021)
article<p>Antiepileptic drugs (AED) with histone deacetylase (HDAC) inhibitor properties decrease prostate cancer (PCa) cell proliferation in vitro. A population-based cohort of 78 615 men was used to evaluate the risk of ... -
Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial
(19.08.2021)
article<p>OBJECTIVE: To evaluate digital rectal examination (DRE) as a predictor of prostate cancer (PC) at serum PSA level 3.0-3.9 ng/ml. We compared the PC incidence rates of men with different screening test results in ... -
Do differences in secondary treatment explain mortality impact of prostate cancer screening?: A randomized screening trial
(06 / 2025)
articleBackground: The European Randomized study of screening for prostate cancer (ERSPC) demonstrated a reduction in prostate cancer (PC) mortality via PSA-based screening. We evaluated whether treatments for castration resistant ... -
Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer
(27.11.2021)
article<p>PURPOSE: Screening for prostate cancer may have limited impact on decreasing prostate cancer-related mortality. A major disadvantage is overdiagnosis, whereby lesions are identified that would not have become ... -
Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study
(09.10.2020)
articleBACKGROUND: The aim of this study is to investigate the potential impact of prostate magnetic resonance imaging (MRI) -related interreader variability on a population-based randomized prostate cancer screening trial ... -
Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study
(2024)
articlePurpose: Prostate cancer (PCa) histology, particularly the Gleason score, is an independent prognostic predictor in PCa. Little is known about the inter-reader variability in grading of targeted prostate biopsy based on ... -
Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level
(14.06.2022)
article<p>Statins have been associated with a decreased cancer mortality. However, cholesterol level as such may modify the risk of cancer death. To clarify the complex interplay between statins, cholesterol level, and ... -
Long-term Risk of Prostate Cancer Mortality Among Men with Baseline Prostate-specific Antigen Below 3 ng/ml: Evidence from the Finnish Randomized Study of Screening for Prostate Cancer
(12 / 2024)
articleBACKGROUND AND OBJECTIVE: Despite the evidence for prostate-specific antigen (PSA) screening reducing prostate cancer (PCa) mortality, the optimal PSA cutoff and the clinical significance of low initial PSA levels in ... -
Mitä kertoa potilaalle, joka haluaa tarkistaa PSA-arvonsa?
(2022)
articleProstataspesifisen antigeenin (PSA) testaamisen selkein käyttöaihe on eturauhassyövän hoidon jälkeinen seuranta. Testi kuuluu myös virtsaamisoireiden diagnostiseen selvittelyyn. Eturauhassyövän seulontatyökaluna PSA-testi ... -
Outcomes of Screening for Prostate Cancer Among Men Who Use Statins
(01.01.2021)
articleImportance: Prostate-specific antigen (PSA) screening for prostate cancer has resulted in a slight reduction in prostate cancer mortality but also a concomitant overdiagnosis of low-risk tumors. Prostate-specific antigen ... -
Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study
(2021)
articleObjectives: To evaluate the feasibility of a population-based screening trial using prostate-specific antigen (PSA), a kallikrein panel and multiparametric magnetic resonance imaging (MRI) aimed at minimizing overdiagnosis, ... -
Prognostic index for predicting prostate cancer survival in a randomized screening trial: Development and validation
(2021)
article<p>We developed and validated a prognostic index to predict survival from prostate cancer (PCa) based on the Finnish randomized screening trial (FinRSPC). Men diagnosed with localized PCa (N = 7042) were included. ... -
Prostate cancer incidence in men with Prostate-Specific Antigen (PSA) below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)
(02.02.2022)
article<p>Prostate-specific antigen (PSA)-based screening for prostate cancer (PCa) can reduce PCa mortality, but also involves over-detection of low-risk disease with potential adverse effects. We evaluated PCa incidence ... -
Prostate Cancer Screening with PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial
(2024)
articleImportance: Prostate-specific antigen (PSA) screening has potential to reduce prostate cancer mortality but frequently detects prostate cancer that is not clinically important. Objective: To describe rates of low-grade ... -
Risk factors for low-risk prostate cancer: A retrospective cohort study within the FinRSPC trial
(11 / 2025)
articleOverdiagnosis of low-risk prostate cancer (PC), often accompanied by overtreatment, remains an important harmful consequence of prostate-specific antigen (PSA)-based screening. Although PSA screening can reduce PC mortality ... -
Screening history and risk of death from prostate cancer: a nested case–control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)
(08.12.2023)
articlePurpose: We assessed the risk of death from prostate cancer (PCa) in relation to men’s screening histories, i.e., screening attendance among men who were offered screening. Methods: Men in the Finnish Randomized Study of ...
